We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA: Surrogate Biomarkers Not Always Sufficient
EMEA: Surrogate Biomarkers Not Always Sufficient
September 2, 2009
Surrogate biomarkers, which measure the effects of drugs on lipid levels in the blood and on blood pressure, are useful in clinical trials but may not provide enough information for a sound risk-benefit assessment, the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) says.